Remember meForgot password?
    Log in with Twitter
Press Release

Rheumatic Disorders Drugs- Growing Popularity and Emerging Trends in the Market

Rheumatic Disorders Drugs Market to Set Astonishing Growth from 2017 to 2024

This press release was orginally distributed by SBWire

Edison, NJ -- (SBWIRE) -- 01/18/2019 -- A new research document with title 'Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry' covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions like North America, South & Central America, Middle East & Africa, Europe, Asia Pacific and important players/vendors. The report will help user gain market insights, future trends and growth prospects for forecast period of 2024

Get customization & check discount for report @

The rheumatic disorder therapy area is multi-disciplinary in nature and encompasses conditions that affect joints, connective tissue, ligaments, tendons, cartilage, bone and muscle and which are characterized by chronic pain and a consequent reduction in function and motion. The majority of rheumatic disorders are treated using largely genericized pain management drugs, and there are no cures for any of the key indications, leaving a large unmet need for better disease-modifying drugs to be developed.
This report covers all rheumatic disorders, but there is a particular focus on five key diseases, rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus and psoriatic arthritis, as these conditions have the largest pipelines within the therapy area.
The market size for rheumatic disorder therapeutics was $58.97 billion in 2017 and is expected to grow at a compound annual growth rate (CAGR) of 4.46% to $80.04 billion in 2024.

View Detailed Table of Content @

- How is the rheumatic disorders landscape expected to change
- Which drugs will face patent expiry, biosimilar competition and decreasing revenue over the forecast period
- Overall, there are 1,069 products in the rheumatic disorder pipeline, how does the composition of the pipeline compare with that of the existing market
- Which molecular targets are most prominent within the pipeline and how do the key indications differ in terms of their pipeline composition
- The market size for rheumatic disorder therapeutics is expected to grow, from $58.97 billion in 2017 to $80.04 billion in 2024, at a CAGR of 4.46%. Which products will contribute to market growth most, and which will achieve blockbuster status
- What types of companies are involved in the rheumatic disorder therapy area
- Will the current market leaders retain their dominance over the forecast period
- How many strategic consolidations have been completed in the past decade and which types of assets attract the largest deal values

Reasons to buy
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the five key indications
- Understand how the patent expiries of the key, blockbuster anti-TNF drugs will affect the rheumatic disorder drug market
- Identify trends and developments in the rheumatic disorder pipeline and consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates
- Identify which two drug classes will see particularly strong market growth over the forecast period
- See how or if the companies marketing anti-TNF drugs facing patent expiry will be able to offset biosimilar erosion
- Identify commercial opportunities in the rheumatic disorder deal landscape by analyzing trends in licensing and co-development deals

Request a sample report @

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 12
2.1 Therapy Area Overview 12
2.2 Etiology 17
2.3 Pathophysiology 19
2.4 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation 23
2.5 Treatment 29

3 Key Marketed Products 40
3.1 Overview 40
3.2 Humira (adalimumab) - AbbVie 41
3.3 Enbrel (etanercept) - Amgen 44
3.4 Simponi (golimumab) - Johnson & Johnson 46
3.5 Remicade (infliximab) - Johnson & Johnson 48
3.6 Rituxan (rituximab) - Roche 51

4 Pipeline Landscape Assessment 64
4.1 Overview 64
4.2 Pipeline Development Landscape 64
4.3 Molecule Types in the Pipeline 67
4.4 Molecular Targets in the Pipeline 68
4.5 Clinical Trials Landscape 70
4.6 Assessment of Key Pipeline Products 85

5 Multi-scenario Market Forecast to 2024 96
5.1 Overall Market Size 96
5.2 Generic Penetration 99
5.3 Revenue Forecast by Molecular Target 101

Place a Purchase Order For Market Study (Single User License) at:

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

For more information on this press release visit:

Media Relations Contact

Criag Francis
Telephone: 206-317-1218
Email: Click to Email Criag Francis

Latest News
Top News